INHIBITION OF PACLITAXEL AGAINST NEUROGLIOMA CELLS U251 GROWTH AND ITS MECHANISM

Authors

  • ShiMeng Xin
  • Fang Yu
  • ChunYan Yang
  • Xia Hao

DOI:

https://doi.org/10.21010/ajtcam.v14i1.19

Keywords:

paclitaxel, antitumour, apoptosis, cell cycle

Abstract

Background: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors. Materials and Methods: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was treated in neuroglioma cellsU251. Results: Paclitaxel significantly inhibited neuroglioma cells growth, and promoted its apoptosis. Paclitaxel can block tumour cells in the G2/M phase. In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment. Conclusion: Our work indicated that paclitaxel displayed strong anti-tumour activity.

Author Biography

ShiMeng Xin

Drug Research & Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria

Downloads

Published

2016-11-23

How to Cite

Xin, S., Yu, F., Yang, C., & Hao, X. (2016). INHIBITION OF PACLITAXEL AGAINST NEUROGLIOMA CELLS U251 GROWTH AND ITS MECHANISM. African Journal of Traditional, Complementary and Alternative Medicines, 14(1), 174–178. https://doi.org/10.21010/ajtcam.v14i1.19

Issue

Vol. 14 No. 1 (2017)

Section

Research Papers

License

Copyright: Creative Commons Attribution CC.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.